Literature DB >> 8652247

Carboplatin and ifosfamide and selective consolidation in advanced seminoma.

R J Amato1, J Ellerhorst, M Banks, C J Logothetis.   

Abstract

This prospective phase II study assesses the clinical efficacy and complications of a treatment regimen comprising combination chemotherapy with carboplatin and ifosfamide and selective consolidation in advanced seminoma. Of 43 patients who entered the study, between May 1989 and May 1992, 42 were evaluable. 30 achieved a complete remission (71%; 95% confidence interval, 56-84%) after chemotherapy alone. 10 achieved a complete remission (24%; 95% confidence interval, 13-39%) after chemotherapy plus consolidation. 38 of the 42 patients (91%; 95% confidence interval, 83-98%) remained in remission after a median follow-up period of 35 months (20-56 months). No patient experienced nephrotoxic, neurotoxic, or ototoxic effects, or haemorrhagic cystitis. Ten per cent of the patients had leucopenic fever requiring hospitalisation. Twenty-four per cent required platelet transfusions, and 26% required transfusions of packed red blood cells. For patients with seminoma, treatment with carboplatin and ifosfamide and selective consolidation is safe and effective.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8652247     DOI: 10.1016/0959-8049(95)00341-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

2.  Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.

Authors:  S Sleijfer; P H Willemse; E G de Vries; W T van der Graaf; H Schraffordt Koops; N H Mulder
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.